| Working Paper |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| Accounting for Price Endogeneity in Airline Itinerary Choice Models: An Application to Continental U.S. Markets |
0 |
1 |
2 |
44 |
0 |
4 |
14 |
66 |
| Assets with "Warts": How Reliable is the Market for Technology? |
0 |
0 |
0 |
7 |
1 |
1 |
3 |
36 |
| Behind the Scenes: Sources of Complementarity in R&D |
0 |
0 |
0 |
16 |
0 |
1 |
4 |
73 |
| Black Populations and Economic Growth: An Extreme Bounds Analysis of Mississippi County-Level Data |
0 |
0 |
2 |
37 |
0 |
1 |
3 |
251 |
| Conveying Quality and Value in Emerging Industries: Star Scientists and the Role of Learning in Biotechnology |
0 |
0 |
0 |
34 |
0 |
2 |
5 |
211 |
| Corporate Venture Capital as a Real Option in the Markets for Technology |
0 |
0 |
1 |
67 |
0 |
2 |
6 |
84 |
| Explaining Preferences for Control Rights in Strategic Alliances: A Property Rights and Capabilities Perspective Approach |
0 |
0 |
0 |
26 |
0 |
1 |
5 |
70 |
| Federal, State, and Local Governments: Evaluating their Separate Roles in US Growth |
0 |
0 |
0 |
61 |
6 |
9 |
28 |
379 |
| Federal, State, and Local Governments: Evaluating their Separate Roles in US Growth |
0 |
0 |
0 |
46 |
0 |
2 |
9 |
355 |
| Federal, State, and Local Governments:Evaluating their Separate Roles in US Growth |
0 |
0 |
1 |
12 |
0 |
1 |
5 |
141 |
| Federal, state, and local governments: evaluating their separate roles in US growth |
0 |
0 |
0 |
0 |
0 |
2 |
5 |
13 |
| Growth and Convergence across the U.S: Evidence from County-Level Data |
0 |
0 |
0 |
254 |
1 |
6 |
16 |
729 |
| Growth and Convergence across the US: Evidence from County-Level Data |
0 |
0 |
0 |
6 |
0 |
2 |
12 |
93 |
| Growth and Convergence across the US: Evidence from County-Level Data |
0 |
0 |
0 |
203 |
0 |
5 |
16 |
593 |
| Growth and Convergence across the US: Evidence from County-Level Data |
0 |
0 |
1 |
10 |
1 |
10 |
19 |
116 |
| Growth and Convergence across the United States: Evidence from County-Level Data |
0 |
0 |
0 |
1 |
1 |
3 |
5 |
11 |
| Heterogeneity in Convergence Rates and Income Determination across U.S. States: Evidence from County-Level Data |
0 |
0 |
0 |
209 |
2 |
4 |
12 |
1,112 |
| Heterogeneity in Convergence Rates and Income Determination across U.S. States: Evidence from County-Level Data |
0 |
0 |
0 |
2 |
2 |
9 |
15 |
69 |
| Heterogeneous Convergence |
0 |
0 |
0 |
14 |
1 |
3 |
8 |
88 |
| Heterogeneous Convergence |
0 |
0 |
0 |
15 |
0 |
3 |
9 |
82 |
| Heterogeneous Convergence |
0 |
0 |
0 |
35 |
7 |
19 |
41 |
308 |
| Heterogeneous Convergence |
0 |
0 |
0 |
56 |
1 |
4 |
14 |
195 |
| Heterogeneous convergence |
0 |
0 |
0 |
1 |
0 |
3 |
7 |
17 |
| Intra-alliance performance, control rights, and today's split of tomorrow's value |
1 |
1 |
1 |
85 |
1 |
2 |
7 |
220 |
| Many Types of Human Capital and Many Roles in U.S. Growth: Evidence from County-Level Educational Attainment Data |
1 |
1 |
5 |
423 |
5 |
10 |
192 |
3,793 |
| Many Types of Human Capital and Many Roles in U.S. Growth: Evidence from County-Level Educational Attainment Data |
0 |
0 |
1 |
9 |
3 |
5 |
16 |
96 |
| Market Size and Research: Evidence from the Pharmaceutical Industry |
0 |
9 |
12 |
12 |
1 |
13 |
23 |
23 |
| Moving Beyond the Valley of Death: Regulation and Venture Capital Investments in Early-Stage Biopharmaceutical Firms |
0 |
0 |
0 |
42 |
0 |
2 |
6 |
55 |
| Regulation and Welfare: Evidence from Paragraph IV Generic Entry in the Pharmaceutical Industry |
0 |
0 |
2 |
53 |
1 |
6 |
16 |
242 |
| Research and Market Structure: Evidence from A Pathogenic Outbreak |
0 |
0 |
1 |
1 |
1 |
1 |
8 |
8 |
| Robust Correlates of County-Level Growth in the U.S |
0 |
0 |
1 |
38 |
0 |
1 |
4 |
169 |
| Robust correlates of county-level growth in the United States |
0 |
0 |
0 |
0 |
0 |
2 |
7 |
9 |
| Sigma Convergence Versus Beta Convergence: Evidence from U.S. County-Level Data |
0 |
0 |
1 |
28 |
0 |
1 |
6 |
119 |
| Sigma Convergence Versus Beta Convergence: Evidence from U.S. County-Level Data (revised version) |
0 |
0 |
0 |
30 |
0 |
1 |
4 |
103 |
| Sigma Convergence versus Beta Convergence: Evidence from U.S. County-Level Data |
0 |
0 |
0 |
145 |
2 |
3 |
7 |
513 |
| Sigma Convergence versus Beta Convergence: Evidence from U.S. County-Level Data |
0 |
0 |
0 |
1 |
0 |
2 |
7 |
18 |
| Sigma-Convergence Versus Beta-Convergence: Evidence from U.S. County-Level Data |
0 |
0 |
2 |
518 |
1 |
4 |
19 |
1,653 |
| Starving (or Fattening) the Golden Goose?: Generic Entry and the Incentives for Early-Stage Pharmaceutical Innovation |
0 |
0 |
1 |
37 |
2 |
7 |
13 |
71 |
| The Direct and Indirect Effects of Small Business Administration Lending on Growth: Evidence from U.S. County-Level Data |
0 |
0 |
0 |
45 |
1 |
4 |
7 |
90 |
| The Direct and Indirect Effects of Small Business Administration Lending on Growth: Evidence from U.S. County-Level Data |
0 |
0 |
1 |
55 |
0 |
1 |
19 |
144 |
| The Effect of Contractual Complexity on Technology Sourcing Agreements |
0 |
0 |
0 |
40 |
0 |
0 |
7 |
253 |
| The Impact of Patenting on New Product Introductions in the Pharmaceutical Industry |
0 |
0 |
1 |
118 |
0 |
1 |
2 |
382 |
| The Role of Assets In Place: Loss of Market Exclusivity and Investment |
0 |
0 |
1 |
7 |
0 |
1 |
9 |
20 |
| Unpacking the effects of adverse regulatory events: Evidence from pharmaceutical relabeling |
0 |
0 |
1 |
13 |
0 |
2 |
8 |
44 |
| Total Working Papers |
2 |
12 |
38 |
2,856 |
41 |
166 |
648 |
13,117 |
LogEc is hosted by the
Örebro University School of Business.